Rheumatoid Arthritis
Systemic autoimmune disease causing joint inflammation and destruction. MSC therapy suppresses dysregulated immune responses and reduces articular damage.
Rheumatoid arthritis is a chronic systemic autoimmune disease characterized by symmetric polyarthritis, synovial inflammation, and progressive joint destruction. Left untreated, RA leads to irreversible cartilage and bone damage, functional disability, and a significantly elevated risk of cardiovascular disease.
RA affects approximately 1% of the global population and is driven by a dysregulated Th1/Th17 immune response, elevated TNF-α, IL-6, and IL-17 cytokines, and the production of autoantibodies including rheumatoid factor and anti-CCP. Conventional DMARDs and biologics control symptoms in many patients but carry significant side effect profiles and lose efficacy over time.
MSC therapy offers an immunological reset — suppressing the pathological immune response at a cellular level rather than blocking a single cytokine pathway.
Allogeneic MSCs have strong, well-characterized immunosuppressive properties. They inhibit proliferation and activity of autoreactive T cells, suppress B-cell differentiation into antibody-producing plasma cells, and induce the expansion of regulatory T cells (Tregs) — all of which are dysregulated in RA. These effects are mediated through direct cell contact and the secretion of IDO, PGE2, IL-10, and TGF-β.
In published clinical trials, MSC infusions have produced significant reductions in DAS28 disease activity scores, CRP, ESR, and joint swelling in patients with refractory RA. Several patients in open-label studies achieved clinical remission and sustained disease-free intervals without ongoing DMARD therapy.
True Regen coordinates joint assessment, serology review, and current medication management before referring the patient to Regen Cord for cell manufacturing and administration.
- Reduction in DAS28 disease activity score
- Decreased joint swelling, pain, and morning stiffness
- Lower inflammatory markers (CRP, ESR, IL-6)
- Reduced requirement for corticosteroids or biologic agents
- Improved physical function and quality of life
- Disease remission in a subset of responsive patients
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.